Ensysce Biosciences (ENSC) News Today → $1,500 to $9,400 in one month? (A.I. Trade List) (From Prosper Trading Academy) (Ad) Free ENSC Stock Alerts $0.68 -0.06 (-8.11%) (As of 05/21/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 6:05 PM | finance.yahoo.comSector Update: Health Care Stocks Softer Late AfternoonMay 14, 2024 | finance.yahoo.comEnsysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 13, 2024 | msn.comENSC: Quarterly Report Highlights ProgressApril 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finance.yahoo.comEnsysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 9, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceMarch 18, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023March 15, 2024 | finance.yahoo.comENSC Striding Toward Opioid ReplacementMarch 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | benzinga.comEnsysce Biosciences Stock (NASDAQ:ENSC), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comEnsysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose ProtectionFebruary 16, 2024 | finance.yahoo.comENSC: Investors Should Pay AttentionFebruary 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 15, 2024 | finance.yahoo.comEnsysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 13, 2024 | msn.comEnsysce Biosciences falls on exercise of warrants for $4.7M gross proceedsFebruary 13, 2024 | finance.yahoo.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross ProceedsFebruary 6, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceFebruary 6, 2024 | finance.yahoo.comEnsysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceJanuary 31, 2024 | finance.yahoo.comEnsysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe PainJanuary 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 25, 2024 | finance.yahoo.comEnsysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 23, 2024 | seekingalpha.comEnsysce rallies 22% on FDA update for overdose-resistant opioidJanuary 23, 2024 | finance.yahoo.comOpioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's WhyJanuary 23, 2024 | finance.yahoo.comENSC Announces Major FDA DesignationJanuary 23, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 23, 2024 | finance.yahoo.comEnsysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 17, 2024 | msn.comEnsysce Biosciences files to sell common stock, warrantsJanuary 8, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Issues 2024 Shareholder LetterJanuary 8, 2024 | finance.yahoo.comEnsysce Biosciences Issues 2024 Shareholder LetterDecember 19, 2023 | finance.yahoo.comEnsysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023December 14, 2023 | finance.yahoo.comEnsysce Biosciences Announces Key Efficacy Data for Lead AnalgesicDecember 11, 2023 | finance.yahoo.comEnsysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day PodcastDecember 7, 2023 | morningstar.comEnsysce Biosciences Inc Ordinary SharesNovember 30, 2023 | marketbeat.comTrading was temporarily halted for "ENSC" at 02:11 PM with a stated reason of "LULD pause."November 29, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge in the United StatesNovember 29, 2023 | finance.yahoo.comEnsysce Biosciences Announces Completion of $1.7 Million Convertible Note FinancingNovember 28, 2023 | finance.yahoo.comEnsysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United StatesNovember 28, 2023 | finance.yahoo.comEnsysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United StatesNovember 16, 2023 | finance.yahoo.comEnsysce Biosciences Announces Enrollment Completion for PF614-201 Clinical StudyNovember 10, 2023 | finance.yahoo.comENSC Releases Earnings and Highlights ProgressNovember 9, 2023 | finance.yahoo.comEnsysce Biosciences Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | finance.yahoo.comEnsysce Biosciences Secures $1.7 Million Convertible Note FinancingOctober 18, 2023 | finance.yahoo.comEnsysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360October 13, 2023 | finance.yahoo.comEnsysce Biosciences Releases "Highlights Video" of PAINWeek 2023 SymposiumOctober 3, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023October 3, 2023 | finance.yahoo.comEnsysce Biosciences to Chair the Fierce New Product Planning Summit 2023September 26, 2023 | finance.yahoo.comEnsysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical StudySeptember 25, 2023 | markets.businessinsider.comEnsysce Biosciences (ENSC) Receives a Buy from H.C. WainwrightSeptember 19, 2023 | finance.yahoo.comEnsysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023September 14, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution ENSC Media Mentions By Week ENSC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENSC News Sentiment▼0.310.44▲Average Medical News Sentiment ENSC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENSC Articles This Week▼11▲ENSC Articles Average Week Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNGX News PTPI News SEEL News ZVSA News CYCC News ALZN News EVOK News GOVX News XCUR News THAR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENSC) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
